Drug Trial Radar · NCT07920861
A Study of HB0017 Injection in Healthy Volunteers to Evaluate Safety and Tolerability of a Single Subcutaneous Injection in Low-Body-Weight Subjects; and Pharmacokinetics at Different Subcutaneous Injection Sites at the Same Dose
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jan 19, 2026
Primary completion
Dec 31, 2026
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Huabo Biopharm Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- First posted
- Nov 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to (PART 1) to evaluate the safety and tolerability of a single subcutaneous injection of HB0017 Injection in healthy subjects with low body weight; ( PART 2) to compare the pharmacokinetics (PK) of HB0017 following single subcutaneous administration at different injection sites at the same dose.
Conditions
- Psoriasis
- Ankylosing Spondylitis
Interventions
HB0017 InjectionBiological
pre-filled syringe, 150 mg/(1 mL)/per injection
HB0017 PlaceboOther
pre-filled syringe,1 mL/per injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse eventsTime frame: through study completion
- CmaxTime frame: From pre-dosing to 140 days post-dosing
- AUCinfTime frame: From pre-dosing to 140 days post-dosing
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First People's Hospital of Hangzhou
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.